About
Paolo Di Giorgio is the CEO and Managing Director of Angelini Ventures, with over 20 years of experience in venture capital, R&D, external innovation, and business development in the life sciences. Before founding Angelini Ventures, he served as Head of External Innovation R&D at Angelini Pharma and previously led drug discovery programs in neuropsychiatry and neurodegeneration at Novartis Pharma in Switzerland. He earned a PhD in Cellular and Molecular Biology from Harvard University and an MBA from IE Business School in Madrid, after graduating from the University of Bologna.
Invests in
BiotechDigital Health
Experience
- Angelini VenturesFounder & CEOcurrent2021 — presentRome, Italy
- Extend | the National Technology Transfer Biotech HubBoard Membercurrent2022 — present
- Arclight TherapeuticsBoard Observercurrent2022 — presentBoston, Massachusetts, United States
- GenEpBoard Observercurrent2021 — present
- Pretzel TherapeuticsBoard Observercurrent2021 — present
- Angelini Lumira Bioscience Fund (ALBF)Member of the Investment committeecurrent2021 — present
- ARGOBIOBoard Membercurrent2021 — present
- Angelini PharmaHead of R&D and External Innovation2016 — 2021Roma, Italia
- NovartisBusiness Development2015 — 2016Basel Metropolitan Area
- NovartisProject team leader2011 — 2016Basel Metropolitan Area
- NovartisLaboratory head of neuroscience and stem cell biology2009 — 2016Basel, Basel, Switzerland
- Salk Institute for Biological StudiesPostdoctoral Fellow2008 — 2009San Diego County, California, United States
- Harvard UniversityPhD student & Postdoctoral Fellow2005 — 2008Greater Boston
- MerckPhD student2002 — 2005Rome, Latium, Italy
- EMBLIntern2000Heidelberg, Baden-Württemberg, Germany
Education
- Harvard UniversityVisiting scholar (Ph.D) and postdoctoral fellow, Neuroscience and stem cell biology2005 — 2008
- IE Business SchoolMaster of Business Administration (M.B.A.)2014 — 2015
- Alma Mater Studiorum – Università di BolognaBachelor's degree, Biotechnology
Skills & more
Lifesciences12Biotechnology36Drug Discovery19Cell Biology33Drug Development10Clinical Development10Neuroscience13Pharmaceutical Industry8Assay Development4Life Sciences32Molecular Biology6Oncology4
+12 more
CellBusiness DevelopmentCross-functional Team LeadershipBusiness StrategyProgram ManagementProject ManagementDepartment ManagementResearch and Development (R&D)StrategyManagementStrategic PlanningLeadershipLanguages English · Italian
From Paolo's professional profile.
Same school
Also attended Harvard University1,231
Alfred LinPartner at Sequoia CapitalChris DixonFounder & Managing Partner of a16z crypto at Andreessen HorowitzSarah TavelVenture Partner at BenchmarkDanny RimerPartner at Index VenturesLaela SturdyManaging Partner at CapitalGRyan IsonoDeal Partner at Felicis Ventures
+ 1,225 more
Also attended IE Business School178
Borja FernándezGeneral Partner at Inveready Technology Investment GroupHayata TokizawaVice President at Fin CapitalIñaki ArrolaInvestor at KfundCarina SzpilkaInvestor at KfundCaroline PhippsSenior Associate at True Beauty VenturesJay HumPrincipal at Mighty Capital
+ 172 more
Also attended Alma Mater Studiorum – Università di Bologna51
Edoardo MingozziPortfolio Support Analyst at P101 VenturesClare McCartney BeerCOO & Managing Director at Burda Principal InvestmentsIrene MingozziVenture Partner at E12 Venture Capital, LlcLuca BarbiGeneral Partner & COO at STVMariana RomeroSenior Associate at NazcaJolene LumHead of Investor Relations at Cento Ventures
+ 45 more
Shared employers
Also worked at Novartis105
Rebecca JamesInvestor at Index VenturesScott BillerInvestor at GV (Google Ventures)Freya Svedberg-KeatingInvestor at MedicxiAndrea AmadorCompliance Manager at Inveready Technology Investment GroupAbbie CelnikerInvestor at Third Rock VenturesJesper GromadaInvestor at Third Rock Ventures
+ 99 more
Also worked at Salk Institute for Biological Studies6
Brittany de KouchkovskyDirector, University Relations at Osage University PartnersRichard HeymanVenture Partner at ARCH Venture PartnersMira ChaurushiyaManaging Director at Westlake Village BioPartnersKatherine ArnoldAnalyst at Ajax HealthKellen HainesVice President at K1 Investment ManagementMichael SmithGeneral Partner at Regeneration.VC
Also worked at Harvard University212
Rachel HansenInvestor at Index VenturesDave MunichielloInvestor at GV (Google Ventures)Logan HilleLife Sciences Analyst at CincyTechWalter KowtoniukInvestor at Third Rock VenturesJefte DrijversInvestor at Third Rock VenturesSamuel ArbesmanVenture Partner at Lux Capital
+ 206 more
Also worked at Merck93
Anika GuptaInvestor at GV (Google Ventures)Sam BlackmanEntrepreneur in Residence at GV (Google Ventures)Catherine Pearce, DHSc, MBAAdvisor at CincyTechDavid MollerInvestor at Third Rock VenturesAndrea van ElsasInvestor at Third Rock VenturesDavid KaufmanInvestor at Third Rock Ventures
+ 87 more
Investments
Board seats
ArgobioNeumirnaPretzel Therapeutics
Per the firm's website.
